Results 151 to 160 of about 145,799,037 (198)

Monoclonal Gammopathy of Undetermined Significance

New England Journal of Medicine, 2007
Monoclonal gammopathy of undetermined significance (MGUS) is a precancerosis comprising two different kinds of cancer: lymphoid/lymphoplasmocytoid MGUS and plasma cell MGUS that represents about 85% of all MGUS cases. This type of MGUS has low but persistent tendency to transform to malignant disease, mainly multiple myeloma (MM), with frequency of ...
MINISOLA, Salvatore, PEPE, JESSICA, E. Romagnoli   +2 more
core   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Monoclonal Gammopathy of Undetermined Significance

Annals of Internal Medicine, 2022
Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical importance to primary care physicians given its high prevalence in the general population. MGUS has a variable but lifelong risk for progression to hematologic cancer, such as multiple myeloma, Waldenström macroglobulinemia, or light-chain amyloidosis.
Wilson I. Gonsalves, S. Vincent Rajkumar
openaire   +2 more sources

Prevalence of Monoclonal Gammopathy of Undetermined Significance

New England Journal of Medicine, 2006
The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premalignant plasma-cell disorder, among persons 50 years of age or older has not been accurately determined. We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area.We identified all living ...
Robert A, Kyle, Terry M, Therneau, S Vincent, Rajkumar, Dirk R, Larson, Matthew F, Plevak, Janice R, Offord, Angela, Dispenzieri, Jerry A, Katzmann, L Joseph, Melton   +8 more
openaire   +4 more sources

Monoclonal Gammopathy of Undetermined Significance

British Journal of Haematology, 2005
SummarySignificant advances have been made in our understanding of the natural history, pathogenesis, mechanisms of progression and prognosis of monoclonal gammopathy of undetermined significance (MGUS). Although the overall incidence of MGUS progression is 1 per year, it is now possible to more accurately predict the risk of progression based on a new
Robert A, Kyle, S Vincent, Rajkumar
openaire   +3 more sources

Monoclonal gammopathies of undetermined significance: a review

Immunological Reviews, 2003
Summary:  Monoclonal gammopathy of undetermined significance (MGUS) denotes the presence of a monoclonal protein (M‐protein) in patients without evidence of multiple myeloma (MM), macroglobulinemia, amyloidosis (AL), or a related plasma cell proliferative disorder.
Robert A, Kyle, S Vincent, Rajkumar
openaire   +2 more sources

Monoclonal Gammopathy of Undetermined Significance

The American Journal of Medicine, 1978
Monoclonal gammopathy of undetermined significance (MGUS) accounted for 56% of the 1026 patients with a monoclonal plasma cell disorder seen at the Mayo Clinic during 1992. Approximately 3% of persons older than 70 years and 1% of those older than 50 years had MGUS.
openaire   +3 more sources

Prognosis in monoclonal gammopathy of undetermined significance

British Journal of Haematology, 1997
Eighty‐seven patients with monoclonal gammopathy of undetermined significance (MGUS) were followed for a period of 1–20 years, median 91 months. Transformation to multiple myeloma occurred in 14 patients of whom seven died as a consequence of the disease. There were 13 unrelated deaths.
Vučković, Joško, Ilić, Anita, Knežević, Nebojša, Marinković, Marija, Zemunik, Tatijana, Dubravčić, Mirko   +5 more
openaire   +3 more sources

[Monoclonal gammopathy of undetermined significance].

Ugeskrift for laeger, 2021
This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of
Niels Emil Ulrich, Hermansen, Trine, Silkjær, Charlotte Toftmann, Hansen, Thomas Granum, Aagaard, Henrik, Gregersen   +4 more
openaire   +3 more sources

Monoclonal gammopathy of undetermined significance: a consensus statement

British Journal of Haematology, 2010
SummaryOn February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non‐malignant B‐cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B‐cell disorders.
Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, PALUMBO, Antonio, Roodman GD, San Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle R.A.   +20 more
openaire   +4 more sources

The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance

Cancer Epidemiology, Biomarkers & Prevention
Abstract The identification of premalignant lesions in solid tumors such as colorectal and cervical cancer has led to the development of highly effective population-wide screening programs for these malignancies.
Lindor Qunaj, Suzanne Lentzsch, Alfred I. Neugut   +2 more
openaire   +2 more sources